A Pilot Study of patients with Oligometastases from Prostate cancer treated with Stereotactic Ablative Body Radiosurgery

Not Applicable

Completed

• Conditions: Metastatic Prostate Cancer (oligometastatic 1-3 metastases); Cancer - Prostate

• Registration Number: ACTRN12613000436774
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

Aged 18 years or older.
Has provided written Informed Consent for participation in this trial.
Histological or cytologically confirmed prostate cancer.
Primary prostate cancer controlled (or planned to be) by surgery or radical radiotherapy.
Bone Scan or CT Scan evidence of 1 to 3 metastases (Bone or Lymph node).
Androgen sensitive and castration-resistant prostate cancer.
An ECOG performance status score of 2 or less.
Life expectancy greater than 12 months.
Available for follow up.

Exclusion Criteria

Previous high dose radiotherapy (Biological Equivalent Dose BED>40Gy) to the area to be treated.
Visceral Metastases (e.g. liver, lung or brain).
Chemotherapy within +/- 3 weeks of Steriotactic Ablative Body Radiotherapy (SABR).
Any change in hormonal therapy regimen within 6 weeks prior to SABR.
Evidence of Spinal Cord Compression
Lesion involving the skull.
Spinal Instability Neoplastic Score greater than or equal to 7 unless lesion reviewed by a neurosurgical service and considered stable.
Long bone Mirels score greater than or equal to 7 unless reviewed by an orthopaedic service and considered stable.
Surgical fixation of lesion required for stability.

Study & Design

• Study Type: Interventional
• Study Design: Not specified